Related Experiment Video

Updated: Aug 17, 2026

Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

The therapeutic potential of chemokine-toxin fusion proteins

J R McDonald1, J L McManaman, V W Yong

  • 1Osprey Pharmaceuticals Limited, 60 Governor Drive SW , Calgary, AB, Canada, T3E 4Y9. jrmcdonald@home.com

Idrugs : the Investigational Drugs Journal
|July 15, 2005
PubMed

Insights

Immune cell activation drives disease pathology. Osprey develops novel cell-targeting agents using chemokine receptor and ligand biology to address these diseases.

Area of Science:

  • Immunology and molecular medicine.

Background:

  • Immune cell activation and their mediators contribute to disease pathology and tissue damage.
  • Current therapies include inhibiting biochemical mediators or eradicating diseased cells.

Purpose of the Study:

  • To develop novel cell-targeting agents.
  • To exploit chemokine receptor and ligand biology for therapeutic applications.

Main Methods:

  • Developing versatile cell-targeting agents.
  • Focusing on the chemokine superfamily of receptors and ligands.

Main Results:

  • Novel cell-targeting agents are under development.
  • The approach leverages chemokine cell biology.

Conclusions:

  • Targeting chemokine pathways offers a new therapeutic strategy.
  • Osprey's approach aims to address diseases driven by immune cell activation.

More Related Videos

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 406:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Related Concept Videos

Fusion of Secretory Vesicles with the Plasma Membrane01:26

Fusion of Secretory Vesicles with the Plasma Membrane

Proteins and neurotransmitters in secretory vesicles can be released from a cell upon vesicle docking, priming, and fusion with the plasma membrane. Vesicles are docked and primed in preparation for the quick exocytosis of their contents in response to a stimulus. The fusion process is mainly carried out by a SNAP Receptor or SNARE complex, consisting of synaptobrevin, syntaxin-1, and SNAP-25.
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
Tagging and Fusion Proteins01:24

Tagging and Fusion Proteins

Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...